Sorafenib in Liver Function Impaired Advanced Hepatocellular Carcinoma

Phase 2 Study of Sorafenib in the Management of Liver Function Impaired Advanced Hepatocellular Carcinoma

Due to the HBV and HCV infection, about 55% hepatocellular carcinoma patients happened in China. Among them, only 10% patients can be diagnosed in early stage. Sorafenib increased PFS and OS in advanced hepatocellular carcinoma patients with liver function of Child-Pugh class A patients, but the result for Child-Pugh class B patients is unclear.

Inclusion Criteria:

• pathological or cytological confirmed advanced hepatocellular carcinoma
• 18 years to 80 years
• liver function Child-Pugh class B
• BCLC stage B or C
• estimated life time 2 months or longer

Exclusion Criteria:

• previous target therapy
• allergy to Sorafenib
• Uncontrolled Bleeding or diarrhea
• eligible for locoregional treatment